| __timestamp | Takeda Pharmaceutical Company Limited | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 4241601.57 |
| Thursday, January 1, 2015 | 650773000000 | 5392385.38 |
| Friday, January 1, 2016 | 619061000000 | 7370036.73 |
| Sunday, January 1, 2017 | 628106000000 | 14970357 |
| Monday, January 1, 2018 | 717599000000 | 31413266 |
| Tuesday, January 1, 2019 | 964737000000 | 72279461 |
| Wednesday, January 1, 2020 | 875663000000 | 183907682 |
| Friday, January 1, 2021 | 886361000000 | 307644000 |
| Saturday, January 1, 2022 | 997309000000 | 472132000 |
| Sunday, January 1, 2023 | 1053819000000 | 709539000 |
| Monday, January 1, 2024 | 1053819000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Takeda Pharmaceutical Company Limited and argenx SE, from 2014 to 2023.
Takeda, a Japanese giant, has consistently demonstrated a robust financial strategy, with SG&A expenses peaking at approximately 1.05 trillion yen in 2023, marking a 72% increase from 2014. In contrast, argenx SE, a Belgian biotech firm, has shown a remarkable growth trajectory, with expenses surging by over 16,600% during the same period, albeit from a much smaller base.
This stark contrast highlights the diverse financial strategies and growth phases of these companies, offering valuable insights into their operational efficiencies and market positioning.
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of GSK plc and argenx SE
Takeda Pharmaceutical Company Limited and Incyte Corporation: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
Takeda Pharmaceutical Company Limited or Xencor, Inc.: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
Takeda Pharmaceutical Company Limited and Evotec SE: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? argenx SE or Summit Therapeutics Inc.
Breaking Down SG&A Expenses: argenx SE vs Perrigo Company plc
argenx SE and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of argenx SE and Supernus Pharmaceuticals, Inc.